Today Barclaycard US, the payments business of Barclays in the United States, announced the launch of the #IHAVEARRIVED Travel Community contest, hosted by Barclaycard Arrival™ MasterCard®. Travel enthusiasts and Barclaycard Arrival cardmembers are invited to join the Barclaycard Travel Community to share their #IHAVEARRIVED travel moment. Barclaycard Arrival cardmembers who enter, have the opportunity to win an exclusive grand prize trip for two to the 58th Annual GRAMMY Awards® in February 2016. Community members who are not Barclaycard Arrival cardmembers have an opportunity to choose between two grand prize options: a West Coast VIP trip for two to Napa Valley, California or an East Coast VIP trip for two to New York City.
“Since launching in 2013, Barclaycard Arrival continues to be recognized by industry experts as the go-to travel card,” said Maurice Ragland, vice president of branded cards. “We make it easy for cardmembers to have once-in-a-lifetime adventures by offering the industry’s best travel rewards program. What better way to showcase these moments than through the #IHAVEARRIVED campaign.”
Travel enthusiasts across the country are encouraged to share memorable travel stories from October 28 through November 22 in the Barclaycard Travel Community. Entries must include a short description and photo of the travel experience. Entries will be judged on originality, creativity, writing and photography.
To view the multimedia release go to:
http://www.multivu.com/players/English/7671251-barclaycard-ihavearrived-launch/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The following is being released by the Notice Provider, Kinsella Media, LLC, about the lawsuit In re Automotive Parts Antitrust Litigation, MDL No. 2311.
Settlements totaling approximately $54.1 million have been reached with two Defendants. The lawsuits allege that they fixed the price of certain motor vehicle components, causing millions of consumers and businesses from around the country to overpay for new or leased automobiles and replacement parts, such as air flow meters, alternators, ATF warmers, electronic throttle bodies, fuel injection systems, ignition coils, inverters, motor generators, radiators, starters, and valve timing control devices.
The Settlements provide monetary relief for consumers in the District of Columbia and 30 states - Arizona, Arkansas, California, Florida, Hawaii, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin. The Settlements also provide non-monetary relief, including cooperation, and an agreement by the Defendants not to engage in certain conduct for a period of 24 months.
To view the multimedia release go to:
http://www.multivu.com/players/English/7666751-auto-parts-antitrust-litigation/
Toys“R”Us® today announced that The Great Big Toys“R”Us Book of Awesome, the company’s annual resource for the year’s hottest toys, will begin arriving in homes this week featuring an all-new, special interactive edition. This 96-page toy compendium is compatible with the company’s all-new app, The Geoffrey Shuffle, a game that allows kids to bring to life the season’s most coveted toys through an augmented reality experience. An abbreviated catalog, which features 48 pages of kid-favorite toys, is now available online at Toysrus.com and will be in local newspapers on Saturday, October 31. This year’s highly-anticipated gift guide from The World’s Greatest Toy Store™ also includes thousands of dollars worth of compelling deals and coupon offers, valid Sunday, November 1 through Saturday, November 21.
“The arrival of The Great Big Toys“R”Us Book of Awesome marks the kickoff of the time-honored tradition of children eagerly studying pages upon pages of the year’s hottest toys, curating their must-have lists for Christmas morning,” said Richard Lennox, Senior Vice President, Chief Marketing Officer, Toys“R”Us, U.S. “Within the book, we created eight interactive lifestyle spreads that show the breadth of our assortment and make bold statements for some of the brands most beloved by kids. This catalog is the centerpiece of our holiday marketing efforts, and extends the theme of “AWWWESOME,” speaking not only to the excitement kids have when they turn the first page, but also the ways the company is helping gift-givers save with great deals and services, such as Price Match Guarantee and Free Shipping.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7476352-toys-r-us-book-of-awesome-2015/
When a serious illness enters a family's life, there are many questions to ask and decisions to make. It is important to answer these questions quickly. The process can seem overwhelming. However, hospice care can be a wonderful resource for information about symptom management and comfort care. Hospice care professionals are available to help assess goals, pain management and care options during the decision-making process.
Are your symptoms minimal or moderate? Are these symptoms just starting to affect your life? If you want to continue treatment but also need comfort and symptom management, palliative care (often called comfort care) maybe an option. Palliative care is patient and family-centered care that optimizes quality of life by anticipating, preventing and treating suffering. Palliative care specialists address the physical, intellectual, emotional, social, and spiritual needs of patients and families, making sure they have access to all the information about the disease progression and the choices ahead. A patient can receive palliative care in conjunction with other treatments or therapies.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Well, this certainly break's my 1 song per month rule. I can't help it. Halloween's got me by the Candy Apples. Normally, I create the music first and then I make a video for it later but I didn't want to go through my video madness routine at the very end and so I did a little bit of this and a little bit of that and got it all wrapped up together at the same time. I didn't have the opportunity to take the song out for a test drive as I always take a cruise with my bro and we listen to it in his car and then later I make some adjustments at home. It sound's fine to me through my laptop and the video look's okay and so I'm just gonna upload it as is.
If there’s one thing that socially responsible businesses have learned, it’s that they can’t go at it alone. Whether it’s implementing responsible sourcing initiatives or creating a positive corporate model to make an impact on sustainability, there is strength in numbers. So where did Ben & Jerry’s turn for help and inspiration for its latest ice cream flavor? Colorado-based New Belgium Brewing. Never has the phrase “polishing off a pint” been so perfectly poised in any partnership for a delicious double-entendre.
Collectively committed to making a better impact in their global communities, the two B Corp companies proudly introduced Salted Caramel Brown-ie Ale ice cream, which will be featured in Ben & Jerry’s Scoop Shops as well as in pints across the country as a Limited Batch flavor this fall (MSRP $4.89). The concoction consists of New Belgium Brown Ale Ice Cream with Salted Caramel Swirls and Fudge Brownies. The ice cream, arriving on shelves this month, was unveiled Wednesday evening at a Washington D.C. launch “Brew-Ha-Ha” in the confines of the historic Howard Theatre. The launch event was heralded as “a night of music, climate activism, beer, and ice cream.” Musicians Galactic and Dr. Dog performed at the unveiling of Ben & Jerry’s newest ice cream flavor to highlight climate activism.
To view the multimedia release go to:
http://www.multivu.com/players/English/7648451-ben-and-jerry-s-new-belgium-brewery/
In celebration of General Mills’ commitment to removing artificial flavors and colors from artificial sources from all of its cereals, the company is rolling out a three-week open casting call to find one real rabbit to be featured as the honorary face of Trix. Pet bunnies from across the country could be the #RealTrixRabbit and appear on limited run boxes in the winner’s hometown.
From real rabbits to pets in bunny costumes, kids, parents and family members are invited to snap pictures or take videos of their furry friends– and upload them to the www.RealTrixRabbit.com. Applicants can also scope out the competition and follow the journey to find the Real Trix Rabbit by following #RealTrixRabbit on social media from October 19, 2015 to November 8, 2015.
While the iconic Trix Rabbit isn’t going anywhere, Trix is removing artificial flavors and colors from artificial sources. This means using ingredients like fruit and vegetable juices and spice extracts such as turmeric and annatto to achieve the fun red, yellow, orange and purple colors while delivering the same great taste that adults and children have always enjoyed.
“The search for the honorary Real Trix Rabbit is a family-friendly opportunity to share our excitement with cereal fans as we introduce the new Trix recipe this January,” said Lauren Pradhan, senior marketing manager for General Mills’ Cereal division. “We are excited for families to experience the new Trix recipe as well as the recipes for other cereals and see for themselves that every spoonful will still deliver the great taste, quality and fun that General Mills cereals have always brought to their cereal bowl.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7664051-real-trix-rabbit/
Today, premium men-s undergarment brand Tommy John launches the lightest men-s underwear ever created, aptly called Air. On the heels of their recently launched viral film campaign “The Big Adjustment”, Tommy John is debuting this collection of underwear and undershirts made from some of the most advanced fabric technology in the world.
After almost two years of product development, which included Founder and CEO Tom Patterson personally wear-testing, washing, drying, weighing and re-weighing the newest product line, Air is now available to the public. As part of the Light category of solution-based products, Air weighs-in at an average of two ounces. The ultra-lightweight and anti-microbial mesh fabric provides wearers maximum ventilation with unmatched durability and superior quick drying features.
“Air isn't only our greatest product achievement to date, but what we believe to be one of the greatest achievement ever for men's undergarments. We were able to create a product at less than half the weight of our competitors with Air,” says Tom Patterson, Founder & CEO of Tommy John. “We have never been so excited for a new collection.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7648931-tommy-john-the-big-adjustment/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
